

Antonio Vitiello

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8437022/publications.pdf>

Version: 2024-02-01

61
papers

1,154
citations

331259

21
h-index

433756

31
g-index

61
all docs

61
docs citations

61
times ranked

811
citing authors

#	ARTICLE	IF	CITATIONS
1	COVID-19 vaccines and decreased transmission of SARS-CoV-2. <i>Inflammopharmacology</i> , 2021, 29, 1357-1360.	1.9	100
2	Advances in the Omicron variant development. <i>Journal of Internal Medicine</i> , 2022, 292, 81-90.	2.7	85
3	The added value of pirfenidone to fight inflammation and fibrotic state induced by SARS-CoV-2. <i>European Journal of Clinical Pharmacology</i> , 2020, 76, 1615-1618.	0.8	64
4	Colchicine and SARS-CoV-2: Management of the hyperinflammatory state. <i>Respiratory Medicine</i> , 2021, 178, 106322.	1.3	44
5	Characterization of serious adverse drug reactions as cause of emergency department visit in children: a 5-years active pharmacovigilance study. <i>BMC Pharmacology & Toxicology</i> , 2018, 19, 16.	1.0	43
6	Brief review of the mRNA vaccines COVID-19. <i>Inflammopharmacology</i> , 2021, 29, 645-649.	1.9	42
7	Pharmacological agents to therapeutic treatment of cardiac injury caused by Covid-19. <i>Life Sciences</i> , 2020, 262, 118510.	2.0	41
8	Remdesivir versus ritonavir/lopinavir in COVID-19 patients. <i>Irish Journal of Medical Science</i> , 2021, 190, 1249-1250.	0.8	38
9	The risks of liver injury in COVID-19 patients and pharmacological management to reduce or prevent the damage induced. <i>Egyptian Liver Journal</i> , 2021, 11, 11.	0.3	38
10	Efficacy of synthetic glucocorticoids in COVID-19 endothelites. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2021, 394, 1003-1007.	1.4	38
11	COVID-19 Patients with Pulmonary Fibrotic Tissue: Clinical Pharmacological Rational of Antifibrotic Therapy. <i>SN Comprehensive Clinical Medicine</i> , 2020, 2, 1709-1712.	0.3	36
12	Therapeutic Strategies for SARS-CoV-2 acting on ACE-2. <i>European Journal of Pharmaceutical Sciences</i> , 2021, 156, 105579.	1.9	35
13	Correlation between renin-angiotensin system and Severe Acute Respiratory Syndrome Coronavirus 2 infection: What do we know?. <i>European Journal of Pharmacology</i> , 2020, 883, 173373.	1.7	34
14	Pharmacological approach for the reduction of inflammatory and prothrombotic hyperactive state in COVID-19 positive patients by acting on complement cascade. <i>Human Immunology</i> , 2021, 82, 264-269.	1.2	33
15	Drugs acting on the renin-angiotensin system and SARS-CoV-2. <i>Drug Discovery Today</i> , 2021, 26, 870-874.	3.2	33
16	Remdesivir and COVID-19 infection, therapeutic benefits or unnecessary risks?. <i>Irish Journal of Medical Science</i> , 2021, 190, 1637-1638.	0.8	32
17	Remdesivir and COVID-19. <i>Irish Journal of Medical Science</i> , 2021, 190, 1237-1238.	0.8	30
18	Sacubitril, valsartan and SARS-CoV-2. <i>BMJ Evidence-Based Medicine</i> , 2021, 26, 205-205.	1.7	29

#	ARTICLE	IF	CITATIONS
19	Scientific hypothesis and rational pharmacological for the use of sacubitril/valsartan in cardiac damage caused by COVID-19. <i>Medical Hypotheses</i> , 2021, 147, 110486.	0.8	28
20	Scientific Hypothesis for Treatment of COVID-19's Lung Lesions by Adjusting ACE/ACE2 Imbalance. <i>Cardiovascular Toxicology</i> , 2021, 21, 498-503.	1.1	28
21	In vitro model of stromal and epithelial immortalized endometriotic cells. <i>Journal of Cellular Biochemistry</i> , 2012, 113, 1292-1301.	1.2	26
22	COVID-19 pandemic: vaccine and new monoclonal antibodies, point of view. <i>Irish Journal of Medical Science</i> , 2021, , 1.	0.8	26
23	The Central Role of Clinical Nutrition in COVID-19 Patients During and After Hospitalization in Intensive Care Unit. <i>SN Comprehensive Clinical Medicine</i> , 2020, 2, 1064-1068.	0.3	20
24	Are multiple sclerosis therapies safe in severe acute respiratory syndrome coronavirus 2 times?. <i>Indian Journal of Pharmacology</i> , 2020, 52, 441.	0.4	18
25	What will be the role of molnupiravir in the treatment of COVID-19 infection?. <i>Drugs and Therapy Perspectives</i> , 2021, 37, 579-580.	0.3	17
26	Cytokine storm and colchicine potential role fighting SARS-CoV-2 pneumonia. <i>Italian Journal of Medicine</i> , 0, , .	0.2	16
27	Potential pharmacological approach in the regulation of angiotensin-II conversion enzyme and dipeptidyl-peptidase 4 in diabetic COVID-19 patients. <i>Italian Journal of Medicine</i> , 2021, 15, .	0.2	16
28	Sars-Cov-2 and risk of antiviral drug resistance. <i>Irish Journal of Medical Science</i> , 2022, 191, 2367-2368.	0.8	14
29	Pandemic COVID-19, an update of current status and new therapeutic strategies. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 0, , .	1.4	14
30	Pharmacological agents modifying the renin angiotensin and natriuretic peptide systems in COVID-19 patients. <i>Wiener Klinische Wochenschrift</i> , 2021, 133, 983-988.	1.0	13
31	Correlation between the use of statins and COVID-19: what do we know?. <i>BMJ Evidence-Based Medicine</i> , 2022, 27, 126-127.	1.7	12
32	Low Molecular Weight Heparin, Anti-inflammatory/Immunoregulatory and Antiviral Effects, a Short Update. <i>Cardiovascular Drugs and Therapy</i> , 2023, 37, 277-281.	1.3	12
33	Pregnancy and COVID-19, focus on vaccine and pharmacological treatment. <i>Journal of Reproductive Immunology</i> , 2022, 151, 103630.	0.8	11
34	Anti-fibrotic therapy for the treatment of pulmonary sequelae in patients healed by COVID-19. <i>Lung India</i> , 2021, 38, 129.	0.3	8
35	The renin-angiotensin system and specifically angiotensin-converting enzyme 2 as a potential therapeutic target in SARS-CoV-2 infections. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2021, 394, 1589-1593.	1.4	8
36	Association and pharmacological synergism of the triple drug therapy baricitinib/remdesivir/rhACE2 for the management of COVID-19 infection. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2022, 395, 99-104.	1.4	8

#	ARTICLE	IF	CITATIONS
37	The advantages of drug treatment with statins in patients with SARS-CoV-2 infection. Wiener Klinische Wochenschrift, 2021, 133, 958-965.	1.0	7
38	Logistics management provides greater efficiency, governance and compliance. International Journal of Clinical Pharmacy, 2021, 43, 1431-1435.	1.0	7
39	A short focus, azithromycin in the treatment of respiratory viral infection COVID-19: efficacy or inefficacy?. Immunologic Research, 2022, 70, 129-133.	1.3	7
40	Plausible Positive Effects of Statins in COVID-19 Patient. Cardiovascular Toxicology, 2021, 21, 781-789.	1.1	6
41	Identification of protein-protein interactions of human HtrA1. Frontiers in Bioscience - Elite, 2011, E3, 1493-1499.	0.9	6
42	Could Decreased Reporting of Suspected Adverse Reactions Generate Future Safety Concerns?. Hospital Pharmacy, 2022, 57, 419-421.	0.4	5
43	Perspectives of association Baricitinib/Remdesivir for adults with Covid-19 infection. Molecular Biology Reports, 2022, 49, 827-831.	1.0	4
44	Pharmacotherapy Based on ACE2 Targeting and COVID-19 Infection. International Journal of Molecular Sciences, 2022, 23, 6644.	1.8	4
45	From HTA to HTCLA: The Clinic and Logistics to Support Health Technology Assessments. Hospital Pharmacy, 2022, 57, 5-6.	0.4	3
46	The impact of COVID-19 in diabetic patient. Archives of Medicine and Health Sciences, 2020, 8, 167.	0.0	3
47	Physiopathology and perspectives for therapeutic treatment of pulmonary fibrotic state in COVID-19 patients. Current Research in Pharmacology and Drug Discovery, 2021, 2, 100056.	1.7	2
48	COVID-19 vaccination in pregnancy. Drugs and Therapy Perspectives, 2021, 37, 313-314.	0.3	2
49	Commentary of the mRNA vaccines COVID-19. Asian Journal of Pharmaceutical Sciences, 2021, 16, 531-532.	4.3	2
50	Pleiotropic effects of AT-1 receptor antagonists in hypoxia induced by cardiac ischaemia. Inflammopharmacology, 2022, , 1.	1.9	2
51	Antidiabetes Agents against Sars-Cov-2 Infection. SN Comprehensive Clinical Medicine, 2020, 2, 2718-2721.	0.3	1
52	Worldwide Recommendations and Therapies for Multiple Sclerosis: Are They Safe in the COVID-19 Pandemic Period?. SN Comprehensive Clinical Medicine, 2020, 2, 1017-1018.	0.3	1
53	Renin Angiotensin System and Covid-19 Infection. Advanced Pharmaceutical Bulletin, 2021, 12, 1-4.	0.6	1
54	Clinical Pharmacology Aspects in Patients Treated with TNF Inhibitors During SARS-Cov-2 Pandemic. Advanced Pharmaceutical Bulletin, 2020, 11, 393-394.	0.6	1

#	ARTICLE	IF	CITATIONS
55	Glyphozines and treatment of cardiac disease. Geriatric Care, 2020, 6, .	0.2	0
56	COVID-19 global pandemic: vaccines and new monoclonal antibodies, aspects to be clarified. Immunologic Research, 2021, 69, 115-116.	1.3	0
57	Is there a need for a treatment for COVID-19-induced diabetes?. Clinical Diabetology, 2020, 9, 378-378.	0.2	0
58	Clinical Pharmacology Aspects in Patients Treated with TNF Inhibitors During SARS-Cov-2 Pandemic. Advanced Pharmaceutical Bulletin, 2021, 11, 393-394.	0.6	0
59	Risk of drug-induced cardiac arrhythmia during COVID-19 therapeutic treatment. Egyptian Heart Journal, 2021, 73, 103.	0.4	0
60	The Role of Vitamin C in the Treatment of Sepsis. Drugs and Therapy Perspectives, 0, , 1.	0.3	0
61	Statins in Alzheimerâ€™s disease (AD). European Journal of Clinical Pharmacology, 2022, , 1.	0.8	0